# A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas

Source: https://onco.cc/trials/nct05415072/  
OnCo record `nct05415072` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of DYP688 in uveal melanoma, run by Novartis Pharmaceuticals, active and no longer recruiting.

## Summary

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas is a phase 1/2 interventional study registered as NCT05415072 by Novartis Pharmaceuticals, with 66 participants enrolled, started 2022-07-04 and due to reach its primary completion in 2027-10-01. Interventions recorded: DYP688.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05415072
- Phase: 1/2
- Setting: A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 66

## Sources

- ClinicalTrials.gov NCT05415072: https://clinicaltrials.gov/study/NCT05415072

## Connected records

- cancers: [Uveal melanoma](https://onco.cc/cancers/uveal-melanoma/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct05415072.json